Similar articles

• Low-dose fondaparinux in suspected heparin-induced thrombocytopenia in the critically ill.

  Wester JP, Leyte A, Oudemans-van Straaten HM, Bosman RJ, van der Spoel JI, Haak EA, Porcelijn L, Zandstra DF. Wester JP, et al. Neth J Med. 2007 Mar;65(3):101-8. Neth J Med. 2007. PMID: 17387236
• Phlegmasia cerulea dolens, cerebral venous thrombosis, and fatal pulmonary embolism due to heparin-induced thrombocytopenic thrombosis syndrome.

  Beland B, Busse H, Loick HM, Ostermann H, Van Aken H. Beland B, et al. Anesth Analg. 1997 Dec;85(6):1272-4. doi: 10.1097/00000539-199712000-00016. Anesth Analg. 1997. PMID: 9390592 No abstract available.
• Fondaparinux for the treatment of patients with acute heparin-induced thrombocytopenia.

  Lobo B, Finch C, Howard A, Minhas S. Lobo B, et al. Thromb Haemost. 2008 Jan;99(1):208-14. doi: 10.1160/TH07-04-0252. Thromb Haemost. 2008. PMID: 18217156 Clinical Trial.
• Fondaparinux and the management of heparin-induced thrombocytopenia: the journey continues.

  Blackmer AB, Oertel MD, Valgus JM. Blackmer AB, et al. Ann Pharmacother. 2009 Oct;43(10):1636-46. doi: 10.1345/aph.1M136. Epub 2009 Sep 8. Ann Pharmacother. 2009. PMID: 19737996 Review.
• [Heparin-induced thrombocytopenia].

  Franchini M, Veneri D. Franchini M, et al. Recenti Prog Med. 2005 Sep;96(9):433-5. Recenti Prog Med. 2005. PMID: 16229325 Review. Italian.